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Abstract
Background Breast cancer (BC) is a disease with variable morphology, clinical behaviour and response to therapy. Identify-
ing factors associated with the progression of early-stage BC can help understand the risk of metastasis and guide treatment 
decisions. Myxovirus resistance 1 (MX1), which is involved in the cellular antiviral mechanism, plays a role in some solid 
tumours; however, its role in invasive BC remains unknown. In this study, we aimed to explore the clinicopathological and 
prognostic significance of MX1 in BC.
Methods MX1 was assessed at the protein level using tissue microarrays from a large well-annotated BC cohort (n = 845). 
The expression of MX1 mRNA was assessed at the transcriptomic level using the Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC; n = 1980) and validated using three publicly available cohorts on Breast Cancer 
Gene-Expression Miner (bc-GenExMiner version 4.4). The associations between MX1 expression and clinicopathological 
factors, and outcome were evaluated.
Results High MX1 protein expression was associated with features of aggressiveness, including large tumour size, high 
tumour grade, high Nottingham prognostic index scores, hormone receptor negativity and high Ki67 expression. High MX1 
expression showed an association with poor patient outcome and it was an independent predictor of short BC-specific survival 
(p = 0.028; HR = 1.5; 95% CI = 1.0–2.2). Consistent with the protein results, high MX1 mRNA levels showed an association 
with features of aggressive behaviour and with shorter survival.
Conclusion This study identified MX1 as an independent predictor of poor outcome in patients with BC. Further functional 
studies are needed to investigate the biological role of MX1 in BC and its potential value as a therapeutic target.
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Introduction
Breast cancer (BC) comprises different diseases that 
show distinct molecular features, clinical behaviour and 
response to therapy. Therefore understanding BC biology 
and defining a personalised therapy method remains a Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1054 9-020-05646 -x) contains 
supplementary material, which is available to authorized users.
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challenge [1]. Deciphering the molecular mechanisms and 
biological processes controlling BC progression is impor-
tant to develop better treatment strategies and ultimately 
improve patient outcome.
One of the interferon‐induced GTPases that belongs to 
the dynamin superfamily of large GTPases is MX1 pro-
tein, also known as MXA, which is encoded by Myxovirus 
resistance 1 (MX1) gene [2]. Previous studies have indi-
cated that MX1 has many features, including a tendency 
to self‐assemble, low affinity for guanosine triphosphate 
(GTP) and high intrinsic rate of GTP hydrolysis. MX1 is 
mainly localised in the cytoplasm and shows a granular 
staining pattern that may be associated with cytoskeletal 
structures [3]. MX1 releases GTP, which plays a role in 
metabolising the protein that contributes to the cellu-
lar antiviral mechanism [4]. MX1 is overexpressed and 
appeared to play a role in a variety of cancers but its effect 
remains controversial. Many interferon-stimulated genes 
(ISGs) can inhibit the motility of the transformed cells 
and the invasion of normal tissues. In most tissues, MX is 
highly induced by the ISG, particularly interferon (IFN) 
α and β. MX1 also has a role in the inhibition of motility 
and invasiveness in some cancers, such as prostate car-
cinoma and melanoma [5, 6]. However, MX1 appears to 
have different effects in other cancers. It was observed that 
reduced MX1 level can suppress apoptosis during can-
cer development [6]. In colorectal cancer, MX1 protein is 
overexpressed and plays a significant role in lymph node 
metastasis. An in vitro study conducted in colorectal car-
cinoma indicated that knockdown of MX1 in colon cancer 
cells inhibits migration and invasion of tumour cells [7]. 
Overexpression of MX1 in BC has been reported previ-
ously in certain IHC subtype, highlighting its correlation 
with immune response and tumour infiltrating lympho-
cytes, TILs [8] and it has been associated with anthracy-
cline-based chemotherapy response [9].
MX1 responds to type-1 IFN and acts as a mediated 
signalling pathway [10]. The decrease in MX1 leads to 
the imperfection of lymphocytes of early and advanced 
stages of BC which is a consequence of IFN-α signalling 
in T and B cells [11]. According to Han et al. [11], IFN-α 
signalling defects in lymphocytes of early and advanced 
staged BC is associated with a decrease MX1 level. Type-
1-IFN influences tumour reduction and development by 
acting on tumour, immune, or even endothelial cells [9] 
and can hinder angiogenesis through vascular endothelial 
growth fact (VEGF) down-regulation [10]. However, the 
prognostic value of MX1 in BC remains to be defined. The 
aim of this study is to investigate the expression of MX1 in 
early-stage (operable) BC and assess its association with 
clinicopathological parameters and patient outcome as a 
potential prognostic factor and a possible therapeutic tar-
get in BC.
Materials and methods
Study cohorts
A large well-characterised early-stage primary operable 
invasive BC cohort from female patients attended at Not-
tingham City Hospital, Nottingham, UK, between 1998 and 
2006 was used in this study as described in previous studies 
[12, 13]. All patients were aged less than or equal to 70 years 
and were treated as per a uniform protocol. Clinicopatho-
logical data were systematically recorded, including patient 
age, menopausal status, tumour grade, tumour size and his-
tological type. None of the patients in this study was offered 
neoadjuvant therapy. During the time of the study cohort 
presentation, patients were treated based on the Nottingham 
local protocol, which was based on the Nottingham prognos-
tic index (NPI) and ER status as previously published [14]. 
Briefly, patients with good prognostic NPI scores (≤ 3.4) 
were not prescribed adjuvant chemotherapy. Patients with 
higher NPI scores were treated with adjuvant chemotherapy 
if they have ER-negative tumours. ER-positive patients were 
treated with hormone therapy.
Hormonal receptor status including oestrogen receptor 
(ER) and progesterone receptor (PgR) was available and 
the positive status was defined as those tumours with ≥ 1% 
immunoreactivity [15, 16]. HER2 and Ki67 status were 
also available. Ki67 positivity was considered when > 10% 
of the tumour cells are positive. The assessment of HER2 
status was carried out using immunohistochemistry and 
a chromogenic in situ hybridisation technique to evalu-
ate the gene amplification for the cases with borderline 
(+ 2). The definition for HER2 positivity was ≥ 10% of 
tumour cells showing intense staining of their membranous 
(score + 3) [15, 17, 18]. Based on the immunohistochem-
istry (IHC) profile, BC molecular subtype data were used, 
including luminal A, luminal B, HER2+ and triple nega-
tive (TN) defined as (Ki67 < 10% (low proliferation); ER+/
HER2−), (Ki67 ≥ 10% (high proliferation); ER+/HER2−), 
(HER2+ irrespective of ER) and (ER−, PgR− and HER2−), 
respectively [19]. To further understand the molecular inter-
actions of these biomarkers, basal cytokeratin (CK5, CK17 
and EGFR), proliferation marker and epithelial mesen-
chymal transition (EMT)-associated markers, comprising 
E-cadherin and N-cadherin, were used [20, 21]. Follow-up 
data were recorded from the date of the primary surgery to 
the time of death due to BC, which is defined as BC-specific 
survival (BCSS) and the time from surgery until developing 
distant metastasis, which is defined as distant-metastasis-
free survival (DMFS).
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MX1 protein expression
Western blot (WB) for antibody specificity validation
Using WB, the primary antibody, rabbit polyclonal anti-
MX1 antibody (ab95926, Abcam, UK), was validated. BC 
cell line lysate, MCF7, and human embryonic kidney (HEK) 
that was used as a control (from the American Type Culture 
Collection, Rockville, MD, USA) were employed for WB 
antibody specificity validation. MX1 antibody was used at 
a dilution of 1:1500 and IRDye 800CW Donkey anti-Rab-
bit fluorescent secondary antibody (LI-COR Biosciences) 
was used at a 1:15,000 dilution. For loading control, 
mouse monoclonal anti-β-actin primary antibody (1:5000, 
Sigma-Aldrich) was used and followed by incubation with 
anti-Mouse fluorescent secondary antibody (LI-COR Bio-
sciences). To detect the protein molecular weight, 20 µg of 
the cell lysate was loaded alongside the protein ladder (Page 
Ruler Plus Prestained Protein Ladder, Thermo Scientific). A 
specific band was detected at the predicted molecular weight 
of ~ 64 kDa using Odyssey Fc scanner and visualised by 
Image Studio 4.0 software (Supplementary Fig. 1).
Immunohistochemistry (IHC)
To assess the pattern of MX1 expression, a representative 
full-face tissue section for invasive BC (n = 10) for different 
molecular BC subtypes, histological types and tumour grade 
were stained to verify the staining homogeneity before the 
staining of tissue microarray (TMA). Tumour samples were 
arrayed as previously prepared as TMA utilising a TMA 
Grand Master® (3DHISTECH®, Budapest, Hungary) [13, 
22]. According to the manufacturer’s recommendations, 
antigen retrieval using citrate buffer pH 6.0 at 1000 W for 
20 min with microwave energy was performed. The MX1 
protein expression was evaluated by IHC utilising the Novo-
castra Novolink™ Polymer Detection Systems kit (Leica, 
Biosystems, UK). Briefly, tissue sections (4  µm) were 
incubated for 60 min with rabbit polyclonal MX1 (dilution 
1:100). A positive control using normal kidney tissue was 
used, whereas omitting the primary antibody was used as a 
negative control.
Scoring of MX1 expression
The evaluation of MX1 cytoplasmic expression was per-
formed utilising a modified histochemical score (H-score) 
for the semi-quantitative analyses of immunoreactivity [23]. 
To produce a range of values between 0 and 300, the staining 
intensity [(0 (negative), 1 (weak), 2 (moderate), 3 (strong)] 
multiplied by the percentage (0–100%) for each intensity of 
representative cells in the tissue. All non-informative cores 
were excluded from the scoring including cores with only 
normal breast tissue or folded tissues during processing 
and cores contain < 15% tumour cells. To calculate inter-
observer concordance, double scoring was blindly per-
formed by AA with (~ 10%) scored by another scorer (IM). 
Based on BCSS, X-tile bioinformatics software version 3.6.1 
(Yale University, USA) was used to generate cut-off points 
to dichotomise MX1 protein into high and low expression 
using an H-score of 110.
MX1 transcriptomic analysis
The Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) (n = 1980) was utilised to assess 
MX1 mRNA expression [24]. Based on the median, a cut-
off to dichotomise the levels of mRNA expression into low 
and high subgroups was employed. The association between 
MX1 mRNA level, clinicopathological factors and patient 
outcome was evaluated. Three more publicly available data-
sets (bc-GenExMiner) version 4.4 (https ://bcgen ex.centr 
egaud uchea u.fr) as a prognostic analytical module were 
also employed in this study to validate the data of META-
BRIC cohort (n = 1980), namely, DNA microarrays Affym-
etrix (n = 4904), RNA-Seq TCGA (n = 1034) and RNA-Seq 
GSE81540 (n = 3678).
Statistical analysis
SPSS® Statistics 24.0 was utilised for the statistical analysis 
(SPSS, Inc., Chicago, IL, USA). To evaluate the concord-
ance rate between both scorers, the interclass correlation 
coefficient (ICC) statistical test was performed. The relation-
ship between the targets and the clinicopathological factors 
was determined using a χ2 test. The correlation between the 
transcriptome and protein levels was assessed by Spearman’s 
rank correlation coefficient. For the univariate survival 
analysis, log-rank test and Kaplan–Meier curves were used. 
Cox regression model including other prognostic co-varia-
bles (tumour grade, nodal stage, tumour size, HER2 status 
and basal phenotype) was used to detect the independent 
prognostic value of MX1. For the whole analysis, p-value 
of < 0.05 was considered significant.
Results
Patterns of MX1 protein expression
Normal breast terminal ductal lobular units displayed a weak 
MX1 cytoplasmic staining. In the tumour cells, when pre-
sent, MX1 was expressed in the cytoplasm with no discern-
ible membranous or nuclear staining observed (Fig. 1).
After the exclusion of non-informative TMA cores, the 
total number of cases suitable for the scoring was 845 out of 
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2000 cases. A strong concordance was found between both 
scorers in MX1 scoring (ICC = 0.959, p < 0.0001). A total 
of 243/845 (28%) of the BC cases showed high expression 
of MX1 protein.
Significance of MX1 protein expression
High MX1 protein expression was significantly associated 
with a large tumour size (p = 0.011), high histological grade, 
poor NPI, hormonal receptor negativity (ER− and PR−) (all 
p < 0.0001), younger age at diagnosis (p = 0.047) and pre-
menopausal status (p = 0.040, Table 1). Based on St. Gallen 
International Expert Guidelines and by using the available 
data in IBC cohorts, high protein expression of MX1 was 
significantly associated with the triple negative subtype 
(p < 0.0001, Table 2).
High MX1 level was also associated with basal-like phe-
notype as defined by the positivity of CK5 (p < 0.0001), 
CK17 (p = 0.002), EGFR (p = 0.007) and expression of 
EMT-related marker E-cadherin negativity (p = 0.003). High 
MX1 level was also associated with the high expression of 
the proliferation marker Ki67 (p < 0.0001, Table 3).
MX1 protein expression and patient outcome
High MX1 protein level showed an association with shorter 
BCSS (p = 0.006) and DMFS (p = 0.011, Fig. 2a, b). When 
the cohort was stratified based on adjuvant chemotherapy, 
high MX1 protein expression was significantly associated 
with shorter BCSS in patients who did not receive chemo-
therapy (p = 0.008) but lost its prognostic value in those who 
were offered such therapy (p = 0.571, Fig. 3a, b). The cohort 
was then stratified based on MX1 expression (high- versus 
low expression subgroups) and the association between adju-
vant chemotherapy and outcome was tested. This revealed 
that in the low MX1 subgroup, chemotherapy was associated 
with shorter BCSS (p = 0.001) whereas in the high MX1 
expression subgroup, chemotherapy was not associated with 
BCSS (p = 0.954, Fig. 3c, d).
In multivariate Cox regression analysis, high MX1 pro-
tein expression was an independent predictor of shorter 
BCSS (p = 0.028; HR = 1.5; 95% CI = 1.0–2.2) regardless 
of tumour grade, nodal stage, tumour size, HER2 status 
and basal phenotype (Table 4). Multivariate Cox regression 
analysis was performed when the cohort was stratified based 
on MX1 expression, in low MX1 protein expression cohort, 
adjuvant chemotherapy was independent predictor of shorter 
BCSS (p = 0.017; HR = 0.493; 95% CI = 0.276–0.879) 
regardless of, tumour grade, nodal stage, tumour size, HER2 
status and basal phenotype (Table 5).
MX1 mRNA expression
Based on the spearman’s rank correlation coefficient, a cor-
relation between MX1 protein and MX1 mRNA expression 
was observed in the Nottingham subset (n = 288) of the 
METABRIC cohort (r = 0.120, p = 0.042) indicating weak 
positive correlation.
Similar to the protein results, high MX1 mRNA expres-
sion was significantly correlated with hormonal status 
negativity and a high tumour grade (both p < 0.0001), posi-
tive axillary lymph node (p = 0.018), basal-like phenotype 
(p < 0.0001), premenopausal status, younger age (both 
p = 0.001) and LVI positivity (p = 0.022, Table 6).
Fig. 1  Photomicrographic images (× 40) for immunohistochemical 
protein expression of MX1 in breast tissue microarray images; MX1 
expression of the cytoplasm in cancer cells was distributed as follows; 
a normal breast terminal duct-lobular, b negative expression in inva-
sive breast carcinoma, and c positive expression in invasive breast 
carcinoma (high expression is attributed to H-score cut-off point of 
110 or more based on X-tile for dichotomisation)
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In METABRIC, high MX1 mRNA was significantly 
associated with poor outcome (p < 0.0001, Fig. 2c). Simi-
lar results were observed using the bc-GenExMiner version 
4.4 for DNA microarray and RNA-Seq cohorts’ analyses. 
Although no significant difference in the outcome was 
observed between MX1 high and low expression in TCGA 
cohort (n = 1034, p = 0.190, Supplementary Fig. 2), a sig-
nificant difference between the high and low MX1 expres-
sions in correlation with the probability of patients’ survival 
was recorded in a DNA microarray cohort (Affymetrix) 
(n = 4904, p = 0.0005, Supplementary Fig. 3) either alone 
or when combined with METBRIC cohort (n = 10,001, 
Table 1  Associations between 
MX1 protein expression and the 
clinicopathological factors in 
breast cancer (n = 845)
Significant p values are in bold
Clinicopathological parameters MX1 expression χ2 (p-value)
Low (N = 602) High (N = 243)
N (%) N (%)
Age (years)
 < 50 222 (68) 105 (32) 3.938 (0.047)
 ≥ 50 423 (74) 148 (26)
Menopausal status
 Pre-menopausal 237 (68) 113 (32) 6.431 (0.040)
 Post-menopausal 406 (75) 137 (25)
 Peri-menopausal 3 (100) 0 (0)
Tumour size (cm)
 < 2 338 (76) 109 (24) 6.497 (0.011)
 ≥ 2 303 (68) 143 (32)
Tumour grade
 Low 129 (91) 13 (9) 52.618 (< 0.0001)
 Moderate 212 (79) 57 (21)
 High 302 (62) 181 (38)
Nodal stage
 1 401 (72) 158 (28) 0.224 (0.894)
 2 188 (72) 74 (28)
 3 55 (74) 19 (25)
Nottingham prognostic index
 Poor 95 (64) 53 (36) 25.829 (< 0.0001)
 Moderate 328 (68) 156 (32)
 Good 218 (84) 43 (16)
Lymph-vascular invasion
 Negative 426 (73) 161 (27) 0.620 (0.431)
 Positive 213 (70) 91 (30)
Oestrogen receptor
 Negative 132 (56) 195 (44) 41.725 (< 0.0001)
 Positive 512 (78) 147 (22)
Progesterone receptor
 Negative 234 (62) 143 (38) 32.813 (< 0.0001)
 Positive 398 (80) 102 (20)
HER2 status
 Negative 538 (71) 216 (29) 0.431 (0.511)
 Positive 84 (74) 29 (26)
Basal phenotype
 Negative 499 (75) 170 (25) 10.583 (0.001)
 Positive 133 (63) 78 (37)
Ki67
 Low 228 (84) 43 (16) 27.456 (< 0.0001)
 High 296 (66) 151 (34)
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p < 0.0001, Supplementary Fig. 4). Additionally, we have 
analysed another RNA-Seq cohort, GSE81540 (n = 3678), 
alone or in combination with TCGA and concluded that 
high MX1 expression was significantly different from low 
expression and has poorer prognostic consequences in both 
situations (p = 0.0020, 0.0086, Supplementary Figs. 5, 6), 
respectively. All in all, out of four cohorts analysed and, 
it was only TCGA cohort, when analysed alone, did not 
show a significant change between the high and low MX1 
expression.
Discussion
MX1 contributes to the progression of cancers with different 
attributions, as noticed in various cancers. Although MX1 
protein activity craves for antiviral activities in the immunity 
system [25, 26], it aids in bringing about a signal that articu-
lates a significant contribution to cancer progression and 
response to treatments, such as chemotherapy procedures. 
Moreover, the gene replicates and regulates the gene tran-
scription in which alteration is set to take place within the 
cancer cells. The progression initiates toward the metastatic 
processes in which cell proliferation, migration and death by 
the cancer are sustained or inhibited by MX1 [27].
MX1 has been demonstrated to play a role in various 
human cancers. It has been speculated that it may be a 
tumour suppressor for IFN therapy [28]. To evaluate the 
transcriptomic and protein expression level of MX1 by IHC, 
we used well-annotated multiple BC cohorts to assess their 
associations with clinicopathological parameters and patient 
outcomes. The results showed an association between MX1 
expression and the clinicopathological features’ character-
istic of aggressive behaviour, which strengthens the putative 
role of MX1 in tumour progression. The weak correlation 
between the mRNA and protein expression of MX1 may 
have resulted from different biological and technical fac-
tors. One of these biological factors is the rate of mRNA 
being translated into proteins which is usually termed ‘trans-
lational efficiency’ which has been shown to significantly 
impact on the correlation between mRNA and protein levels 
[29]. Another reason might be attributed to the subjectivity 
of H-score approach in the interpretation of the expression 
of IHC-staining sections [30] and the fact that the META-
BRIC cases used whole tissue comprising many different 
cell types.
A study has revealed that MX1 is a target for repression of 
SATB1. Genome organiser SATB1 can promote BC tumour 
growth and can lead to metastasis by reprogramming SATB1 
expression [31]. The pro-proliferative PIK3/AKT pathway 
plays a role in the regulatory cascade-enhancing MX1 
expression in response to IFNα. In relapsing patients, the 
overexpression of MX1 may be a result of the induction of 
growth signalling by different pathways [32]. In this study, 
an association between MX1 grade and the proliferation 
marker Ki67 is identified.
In different types of cancers, ISGs are largely expressed. 
IFNs play a significant role in various pathways associated 
with malignancies. A study revealed that in HER2-positive 
BCs, MX1 is only expressed in the cytoplasm of tumour 
cells. Moreover, high histological grade and intense infiltrate 
of TILs are correlated with the expression of MX1 protein. 
Type I IFNs lead to T-cell exhaustion by the overexpres-
sion of tumour programmed cell death ligand 1 (PD-L1) 
and the increase of PD-L1 level, which can interact with 
programmed death 1 on T cells [8].
In this study, high MX1 protein was significantly asso-
ciated with EGFR and the loss of E-cadherin, which can 
regulate migration, EMT and invasion [33]. Thus, through 
EMT, which is an important mechanism for metastasis of 
breast carcinoma cells, MX1 may play an essential role in 
the regulation of tumour progression [34].
Table 2  The association between MX1 protein expression and differ-
ent IHC subtypes
Significant p values are in bold
IHC subtypes MX1 expression χ2 (p-value)
Low (N = 549)
N (%)
High (N = 224)
N (%)
Luminal A 172 (85) 31 (15) 67.991 
(< 0.0001)Luminal B 214 (74) 74 (26)
HER2 enriched 83 (74) 29 (26)
Triple negative 80 (47) 90 (53)
Table 3  The association between MX1 protein expression and basal 
and epithelial mesenchymal transition (EMT) biomarkers
Significant p values are in bold
Biomarkers MX1 expression χ2 (p-value)
Low (N = 648) High (N = 253)
N (%) N (%)
CK5
 Negative 411 (73) 153 (27) 25.563 (< 0.0001)
 Positive 58 (49) 60 (51)
CK17
 Negative 391 (73) 144 (27) 9.553 (0.002)
 Positive 52 (57) 39 (43)
EGFR
 Negative 519 (74) 183 (26) 7.401 (0.007)
 Positive 114 (64) 65 (36)
E-cadherin
 Negative 202 (66) 105 (34) 9.077 (0.003)
 Positive 423 (75) 138 (25)
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Additionally, high expression of MX1 was associated 
with the highly proliferative basal phenotype (CK5 and 
CK17) [35–37]. To initiate and establish a metastatic cas-
cade, proliferation and invasion must be occurred to the adja-
cent tissue by the primary tumour cells. At the same time, 
the evasion of apoptosis and immune responses occurs with 
the tumour cells [38]. Thus, in cell proliferation, a prerequi-
site stage of the metastatic process, MX1 may have a role. 
Furthermore, the elevated level of these basal cytokeratins 
(CK5 and CK17) in patients with high MX1 expression 
confers a poor prognosis. Cytokeratins are strongly asso-
ciated with aggressive behaviours of the tumours such as 
high histological grade, hormonal receptor negativity and 
worse outcome [39, 40]. This further supports our results 
and implies that MX1 plays a role in tumourigenic pathways.
The results indicate that MX1 is a potential prognos-
tic biomarker in IBC particularly in patients not receiving 
chemotherapy. Interestingly, our analysis of the overall 
cohort showed that high MX1 level in patients who were 
not offered chemotherapy was associated with poor out-
come in comparison with those who received chemothera-
peutic drugs. Consequently, MX1 prognostic value seems 
to be invalidated when patients were offered chemotherapy. 
Whether this phenomenon can be exploited to monitor the 
chemotherapy effectiveness or not remains ambiguous and 
required further clinical studies to be approved. The MX1 
prognostic value has been validated by the publicly available 
domains. The results demonstrated that high MX1 expres-
sion was correlated with shorter survival in BC patients, in 
three large datasets out of the four cohorts tested. The cor-
relation between MX1 and outcome was also maintained 
throughout the follow-up period indicating that the impact 
of MX1 on the outcome is not time dependent.
Although this study presents interesting findings, some 
hypothetical limitations were determined. Firstly, it is based 
on a retrospectively collected cohort. Secondly, the cut-off 
point used in the protein level analysis was not prespecified 
and was based on X-tile, which was determined based on 
the prediction of patient survival and that different cut-off 
points may result in different categorisation of MX1. Finally, 
a proper assessment of the expression of MX1 in a well-
designed randomised clinical trial where patients are treated 
in a uniform fashion is recommended.
In conclusion, MX1 plays a role in BC associated with 
features of aggressive behaviour and is an independent 
prognostic marker associated with shorter survival. Its 
Fig. 2  Kaplan–Meier survival plots showing the association between MX1, a the protein expression and patient outcome, b the protein expres-
sion and distant metastasis and c mRNA expression (METABRIC) and patient outcome
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prognostic value is influenced by chemotherapy use; how-
ever, it is recommended for these results to be verified in a 
randomised clinical trial setting. Further functional studies 
in vitro and/or in vivo of the biological role of MX1 in BC 
cell lines are necessary to investigate its potential use as a 
therapeutic target in BC.
Fig. 3  Kaplan–Meier survival plot showing the association between 
the expression of MX1 protein and breast cancer-specific survival 
in the invasive breast cancer cohort in a patients have not received 
chemotherapy, b patients received chemotherapy, c chemotherapy vs 
non-chemotherapy classes in patients with high MX1 and d chemo-
therapy vs non-chemotherapy classes in patients with low MX1
Table 4  Multivariate Cox regression for predictors of breast cancer-
specific survival and MX1 protein expression in invasive breast can-
cer
Significant p values are in bold
Parameter Hazard 
ratio 
(HR)
95% Confi-
dence interval 
(CI)
p-value
Lower Upper
MX1 protein expres-
sion
1.5 1.0 2.2 0.028
Tumour grade 3.5 2.1 5.8  < 0.0001
Nodal stage 2.3 1.8 2.9  < 0.0001
Tumour size 1.5 0.9 2.3 0.056
HER2 2.0 1.3 3.1 0.001
Basal phenotype 1.6 1.1 2.3 0.022
Table 5  Multivariate Cox regression for predictors of breast cancer-
specific survival and adjuvant chemotherapy in low MX1 protein 
expression in invasive breast cancer
Significant p values are in bold
Parameter Hazard 
ratio 
(HR)
95% Confi-
dence interval 
(CI)
p-value
Lower Upper
Adjuvant chemo-
therapy
0.493 0.276 0.879 0.017
Tumour grade 3.3 1.5 7.3 0.003
Nodal stage 3.0 2.0 4.4  < 0.0001
Tumour size 1.0 0.587 1.8 0.942
HER2 1.5 0.781 3.0 0.216
Basal phenotype 1.3 0.708 2.3 0.416
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Table 6  Association between 
MX1 mRNA expression and 
clinicopathological parameters 
in the METABRIC (n = 1980)
Significant p values are in bold
Clinicopathological parameters METABRIC cohort χ2 (p-value)
Low (N = 990) High (N = 990)
N (%) N (%)
Age (years)
 < 50 183 (43) 241 (57) 10.096 (0.001)
 ≥ 50 807 (52) 749 (48)
Menopausal status
 Pre-menopausal 189 (43) 247 (57) 10.138 (0.001)
 Post-menopausal 797 (52) 736 (48)
Tumour size (cm)
 < 2 330 (53) 292 (47) 3.177 (0.075)
 ≥ 2 652 (49) 686 (51)
Tumour grade
 Low 118 (69) 52 (31) 103.008 (< 0.0001)
 Moderate 453 (59) 317 (41)
 High 363 (38) 589 (62)
Lymph-vascular invasion
 Negative 481 (52) 449 (48) 5.244 (0.022)
 Positive 291 (46) 344 (54)
Nodal status
 Negative 544 (53) 491 (47) 5.596 (0.018)
 Positive 443 (47) 495 (53)
Oestrogen receptor
 Negative 170 (36) 304 (64) 49.805 (< 0.0001)
 Positive 820 (54) 686 (46)
Progesterone receptor
 Negative 395 (42) 545 (58) 45.571 (< 0.0001)
 Positive 595 (57) 445 (43)
HER2 status
 Negative 880 (51) 853 (49) 3.372 (0.066)
 Positive 110 (44) 137 (56)
Intrinsic molecular classes
 Luminal A 452 (63) 266 (37) 140.785 (< 0.0001)
 Luminal B 223 (46) 265 (54)
 HER2 enriched 111 (46) 129 (54)
 Basal like 83 (25) 246 (75)
 Normal like 118 (59) 81 (41)
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adaptation, distribution and reproduction in any medium or format, 
as long as you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons licence, and indicate 
if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless 
indicated otherwise in a credit line to the material. If material is not 
included in the article’s Creative Commons licence and your intended 
use is not permitted by statutory regulation or exceeds the permitted 
use, you will need to obtain permission directly from the copyright 
holder. To view a copy of this licence, visit http://creativecommons.
org/licenses/by/4.0/.
References
 1. Dawson SJ, Rueda OM, Aparicio S, Caldas C (2013) A new 
genome-driven integrated classification of breast cancer and its 
implications. EMBO J 32(5):617–628. https ://doi.org/10.1038/
emboj .2013.19
 2. Verhelst J, Hulpiau P, Saelens X (2013) Mx proteins: antiviral 
gatekeepers that restrain the uninvited. Microbiol Mol Biol Rev 
77(4):551–566. https ://doi.org/10.1128/MMBR.00024 -13
 3. Haller O, Kochs G (2002) Interferon-induced mx proteins: 
dynamin-like GTPases with antiviral activity. Traffic (Cph Den) 
3(10):710–717
 4. Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun 
L, Boerner SA, Zoratti GL, Stark K, LoRusso PM, Burger A 
(2015) Protein expression of DNA damage repair proteins dic-
tates response to topoisomerase and PARP inhibitors in triple-
negative breast cancer. PLoS ONE 10(3):e0119614. https ://doi.
org/10.1371/journ al.pone.01196 14
 5. Borden EC (2015) 53-Interferons. In: Mendelsohn J, Gray JW, 
Howley PM, Israel MA, Thompson CB (eds) The molecular 
basis of cancer, 4th edn. Content Repository Only!, Philadel-
phia, pp 739–752.e737. https ://doi.org/10.1016/B978-1-4557-
4066-6.00053 -6
 6. Calmon MF, Rodrigues RV, Kaneto CM, Moura RP, Silva SD, 
Mota LD, Pinheiro DG, Torres C, de Carvalho AF, Cury PM, 
Nunes FD, Nishimoto IN, Soares FA, da Silva AM, Kowalski 
LP, Brentani H, Zanelli CF, Silva WA Jr, Rahal P, Tajara EH, 
Carraro DM, Camargo AA, Valentini SR (2009) Epigenetic 
silencing of CRABP2 and MX1 in head and neck tumors. Neo-
plasia (New York, NY) 11(12):1329–1339
 7. Croner RS, Sturzl M, Rau TT, Metodieva G, Geppert CI, Nasch-
berger E, Lausen B, Metodiev MV (2014) Quantitative pro-
teome profiling of lymph node-positive vs. -negative colorectal 
carcinomas pinpoints MX1 as a marker for lymph node metas-
tasis. Int J Cancer 135(12):2878–2886. https ://doi.org/10.1002/
ijc.28929 
 8. Lee SJ, Hwang CS, Kim YK, Lee HJ, Ahn SJ, Shin N, Lee JH, 
Shin DH, Choi KU, Park DY, Lee CH, Huh GY, Sol MY, Lee HJ, 
Gong G, Kim JY, Kim A (2017) Expression of myxovirus resist-
ance A (MxA) is associated with tumor-infiltrating lymphocytes 
in human epidermal growth factor receptor 2 (HER2)-positive 
breast cancers. Cancer Res Treat Off J Korean Cancer Assoc 
49(2):313–321. https ://doi.org/10.4143/crt.2016.098
 9. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, 
Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani 
D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, 
Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili 
P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti 
R, Spano J-P, Pusztai L, Poirier-Colame V, Delaloge S, Penault-
Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers M-C, Egger-
mont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville 
X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André 
F, Kroemer G, Zitvogel L (2014) Cancer cell-autonomous contri-
bution of type I interferon signaling to the efficacy of chemother-
apy. Nat Med 20(11):1301–1309. https ://doi.org/10.1038/nm.3708
 10. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G (2015) 
Type I interferons in anticancer immunity. Nat Rev Immunol 
15(7):405–414. https ://doi.org/10.1038/nri38 45
 11. Han Y-Y, Liu H-Y, Han D-J, Zong X-C, Zhang S-Q, Chen Y-Q 
(2013) Role of glycosylation in the anticancer activity of antibac-
terial peptides against breast cancer cells. Biochem Pharmacol 
86(9):1254–1262. https ://doi.org/10.1016/j.bcp.2013.08.008
 12. Miligy IM, Gorringe KL, Toss MS, Al-Kawaz AA, Simpson P, 
Diez-Rodriguez M, Nolan CC, Ellis IO, Green AR, Rakha EA 
(2018) Thioredoxin-interacting protein is an independent risk 
stratifier for breast ductal carcinoma in situ. Mod Pathol Off J 
US Can Acad Pathol 31(12):1807–1815. https ://doi.org/10.1038/
s4137 9-018-0086-7
 13. Sonbul SN, Aleskandarany MA, Kurozumi S, Joseph C, Toss MS, 
Diez-Rodriguez M, Nolan CC, Mukherjee A, Martin S, Caldas C, 
Ellis IO, Green AR, Rakha EA (2018) Saccharomyces cerevisiae-
like 1 (SEC14L1) is a prognostic factor in breast cancer associ-
ated with lymphovascular invasion. Mod Pathol Off J US Can 
Acad Pathol 31(11):1675–1682. https ://doi.org/10.1038/s4137 
9-018-0092-9
 14. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi 
Z, Blamey RW, Ellis IO (2008) Prognostic significance of Not-
tingham histologic grade in invasive breast carcinoma. J Clin 
Oncol Off J Am Soc Clin Oncol 26(19):3153–3158. https ://doi.
org/10.1200/jco.2007.15.5986
 15. Rakha EA, Pinder SE, Bartlett JMS, Ibrahim M, Starczynski J, 
Carder PJ, Provenzano E, Hanby A, Hales S, Lee AHS, Ellis IO, 
National Coordinating Committee for Breast Pathology (2015) 
Updated UK Recommendations for HER2 assessment in breast 
cancer. J Clin Pathol 68(2):93–99. https ://doi.org/10.1136/jclin 
path-2014-20257 1
 16. Rakha EA, Agarwal D, Green AR, Ashankyty I, Ellis IO, Ball 
G, Alaskandarany MA (2017) Prognostic stratification of oestro-
gen receptor-positive HER2-negative lymph node-negative class 
of breast cancer. Histopathology 70(4):622–631. https ://doi.
org/10.1111/his.13108 
 17. Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan 
CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas C, Mad-
husudan S, Ellis IO, Rakha EA (2016) MYC functions are specific 
in biological subtypes of breast cancer and confers resistance to 
endocrine therapy in luminal tumours. Br J Cancer 114(8):917–
928. https ://doi.org/10.1038/bjc.2016.46
 18. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty 
KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes 
M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller 
K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, 
Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, 
Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff 
AC (2010) American Society of Clinical Oncology/College of 
American Pathologists guideline recommendations for immuno-
histochemical testing of estrogen and progesterone receptors in 
breast cancer. Arch Pathol Lab Med 134(6):907–922. https ://doi.
org/10.1043/1543-2165-134.6.907
 19. Aljohani AI, Toss MS, Kurozumi S, Joseph C, Aleskandarany 
MA, Miligy IM, Ansari RE, Mongan NP, Ellis IO, Green AR, 
Rakha EA (2019) The prognostic significance of wild-type isoci-
trate dehydrogenase 2 (IDH2) in breast cancer. Breast Cancer Res 
Treat. https ://doi.org/10.1007/s1054 9-019-05459 -7
 20. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Rob-
ertson JFR, Macmillan D, Blamey RW, Ellis IO (2005) High-
throughput protein expression analysis using tissue microar-
ray technology of a large well-characterised series identifies 
Breast Cancer Research and Treatment 
1 3
biologically distinct classes of breast cancer confirming recent 
cDNA expression analyses. Int J Cancer 116(3):340–350. https ://
doi.org/10.1002/ijc.21004 
 21. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green 
AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet J-S, Akslen 
LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO 
(2009) Triple-negative breast cancer: distinguishing between basal 
and nonbasal subtypes. Clin Cancer Res 15(7):2302. https ://doi.
org/10.1158/1078-0432.CCR-08-2132
 22. El Ansari R, Craze ML, Miligy I, Diez-Rodriguez M, Nolan CC, 
Ellis IO, Rakha EA, Green AR (2018) The amino acid transporter 
SLC7A5 confers a poor prognosis in the highly proliferative 
breast cancer subtypes and is a key therapeutic target in luminal 
B tumours. Breast Cancer Res 20(1):21. https ://doi.org/10.1186/
s1305 8-018-0946-6
 23. McCarty KS Jr, McCarty KS Sr (1984) Histochemical approaches 
to steroid receptor analyses. Semin Diagn Pathol 1(4):297–308
 24. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dun-
ning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, 
Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Lan-
gerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson 
P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-
Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The 
genomic and transcriptomic architecture of 2,000 breast tumours 
reveals novel subgroups. Nature 486(7403):346–352. https ://doi.
org/10.1038/natur e1098 3
 25. Jiang C-Y, Gao Y, Wang X-J, Ruan Y, Bei X-Y, Wang X-H, Jing 
Y-F, Zhao W, Jiang Q, Li J, Han B-M, Xia S-J, Zhao F-J (2016) 
Long non-coding RNA lnc-MX1-1 is associated with poor clinical 
features and promotes cellular proliferation and invasiveness in 
prostate cancer. Biochem Biophys Res Commun 470(3):721–727. 
https ://doi.org/10.1016/j.bbrc.2016.01.056
 26. Hu J-L, Hua Y-J, Chen Y, Yu B, Gao S (2015) Structural analy-
sis of tumor-related single amino acid mutations in human MxA 
protein. Chin J Cancer 34(12):583–593. https ://doi.org/10.1186/
s4088 0-015-0055-1
 27. Brown SG, Knowell AE, Hunt A, Patel D, Bhosle S, Chaudhary 
J (2015) Interferon inducible antiviral MxA is inversely associ-
ated with prostate cancer and regulates cell cycle, invasion and 
Docetaxel induced apoptosis. Prostate 75(3):266–279. https ://doi.
org/10.1002/pros.22912 
 28. Donnelly LA, Donnelly CR, Xie Y, Bellile EL, Wolf GT, Lei Y 
(2017) An expanded cohort analysis of the prognostic value of the 
Type I interferon signature Gene MX1 in head and neck squamous 
cell carcinoma. J Oral Maxillofac Surg 75(10):e395–e396. https 
://doi.org/10.1016/j.joms.2017.07.121
 29. Maier T, Güell M, Serrano L (2009) Correlation of mRNA and 
protein in complex biological samples. FEBS Lett 583(24):3966–
3973. https ://doi.org/10.1016/j.febsl et.2009.10.036
 30. Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen 
J, Skubitz AP, Metzger GJ, Schmechel SC (2012) Quantitative 
comparison of immunohistochemical staining measured by digital 
image analysis versus pathologist visual scoring. Diagn Pathol 
7:42–42. https ://doi.org/10.1186/1746-1596-7-42
 31. Mushinski JF, Nguyen P, Stevens LM, Khanna C, Lee S, Chung 
EJ, Lee MJ, Kim YS, Linehan WM, Horisberger MA, Trepel JB 
(2009) Inhibition of tumor cell motility by the interferon-inducible 
GTPase MxA. J Biol Chem 284(22):15206–15214. https ://doi.
org/10.1074/jbc.M8063 24200 
 32. Johansson HJ, Sanchez BC, Forshed J, Stal O, Fohlin H, Lewen-
sohn R, Hall P, Bergh J, Lehtio J, Linderholm BK (2015) Prot-
eomics profiling identify CAPS as a potential predictive marker 
of tamoxifen resistance in estrogen receptor positive breast 
cancer. Clin Proteomics 12(1):8. https ://doi.org/10.1186/s1201 
4-015-9080-y
 33. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi 
GN, Ueno NT (2012) Role of epidermal growth factor receptor 
in breast cancer. Breast Cancer Res Treat 136(2):331–345. https 
://doi.org/10.1007/s1054 9-012-2289-9
 34. Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lap-
inska K, Willbanks A, Sarkar S (2015) EMT and tumor metas-
tasis. Clin Transl Med 4(1):6. https ://doi.org/10.1186/s4016 
9-015-0048-3
 35. Laakso M, Loman N, Borg Å, Isola J (2005) Cytokeratin 5/14-pos-
itive breast cancer: true basal phenotype confined to BRCA1 
tumors. Mod Pathol 18(10):1321–1328. https ://doi.org/10.1038/
modpa thol.38004 56
 36. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, 
Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha 
EA, Richardson AL, Schmitt FC, Tan P-H, Tse GM, Weigelt B, 
Ellis IO, Reis-Filho JS (2010) Basal-like and triple-negative breast 
cancers: a critical review with an emphasis on the implications 
for pathologists and oncologists. Mod Pathol 24:157. https ://doi.
org/10.1038/modpa thol.2010.200
 37. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, 
Koller M, Gerstenhauer M, Ortmann O (2013) Ki-67 is a prog-
nostic parameter in breast cancer patients: results of a large pop-
ulation-based cohort of a cancer registry. Breast Cancer Res Treat 
139(2):539–552. https ://doi.org/10.1007/s1054 9-013-2560-8
 38. Hunter KW, Crawford NPS, Alsarraj J (2008) Mechanisms 
of metastasis. Breast Cancer Res 10(Suppl 1):S2. https ://doi.
org/10.1186/bcr19 88
 39. Alshareeda AT, Soria D, Garibaldi JM, Rakha E, Nolan C, Ellis 
IO, Green AR (2013) Characteristics of basal cytokeratin expres-
sion in breast cancer. Breast Cancer Res Treat 139(1):23–37. https 
://doi.org/10.1007/s1054 9-013-2518-x
 40. Kordek R, Potemski P, Kusinska R, Pluciennik E, Bednarek A 
(2010) Basal keratin expression in breast cancer by quantification 
of mRNA and by immunohistochemistry. J Exp Clin Cancer Res 
29:39. https ://doi.org/10.1186/1756-9966-29-39
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
